PATENT CLAIM ANALYSIS

Application Number: 15778615
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-05
Patent Classification: ["424", "139100"]

Abstract:
A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

Claim (Index 17):
The anti-\u03b1v integrin antibody DI17E6, or a biologically active variant or modification thereof, for use according to  claim 1 , wherein said treatment comprises the administration of said antibody, or biologically active variant or modification thereof, in an amount of about 500 mg per month, about 1000 mg per month, about 1500 mg per month, about 2000 mg per month or about 2500 mg per month.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.24324
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10966845', '14390562', '15852977', '13445759', '10484329']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7020386644049665
- 35 USC 102 Novelty (BERT): 0.524831137024839
- Combined Prediction Score: 0.6843179116669539
- Mean Citation Score: 293.606982
- Max Citation Score: 312.09485
- Similarity Product: 180.3013304494024

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test